Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
RYTM - Rhythm Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$140.20
DETAILS
HIGH:
$157.00
LOW:
$125.00
MEDIAN:
$143.00
CONSENSUS:
$140.20
UPSIDE:
59.61%
Stock News
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France –
My Top 3 Stocks to Buy in May
Forget "sell in May and go away." These stocks are good picks to buy and hold.
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported better-than-expected first-quarter financial results on Tuesday.
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Bank of America Global Healthcare Conference on Wednesday, May 13 at 3:00 p.m.
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.81 per share a year ago.
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
-- IMCIVREE ® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- -- First quarter 2026 net product revenue from global sales of IMCIVREE of $60.1 million -- -- IMCIVREE granted Marketing Authorization by European Commission for the treatment of obesity and control of hunger in patients with acquired hypothalamic obesity -- -- Japanese regulatory review of New Drug Application for setmelanotide to treat acquired hypothalamic obesity underway -- -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the first quarter ended March 31, 2026.
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy -- -- Weight category improvements observed in pediatric patients with acquired hypothalamic obesity treated with setmelanotide -- BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the presentation of new data to be delivered by Rhythm and its partners at The Pediatric Endocrine Society (PES) Annual Meeting, taking place April 30-May 3, 2026, in San Francisco. “Acquired hypothalamic obesity is a complex disease that requires long-term management, particularly in pediatric patients,” said Jennifer Miller, M.D.
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment --
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
BOSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8 a.m. ET on Tuesday, May 5, 2026 to report its first quarter 2026 financial results and provide a corporate update.
SG Americas Securities LLC Lowers Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM
SG Americas Securities LLC reduced its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) by 40.0% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,741 shares of the company's stock after selling 7,813 shares during the period. SG
Rhythm Pharmaceuticals Announces Changes to Board of Directors
-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced changes to its Board of Directors, including the appointment of Kim Popovits and the departure of Ed Mathers.
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is This Weight Loss Drug Stock a Buy After a New Approval?
This little-known biotech company has a different strategy than the established weight-loss drug market leaders. But is it likely to be successful?
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
-- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending to expand the current marketing authorization for IMCIVREE® (setmelanotide) to include the treatment of obesity and the control of hunger in adults and children 4 years of age and above with acquired hypothalamic obesity (HO) due to hypothalamic injury or impairment.
Rhythm Pharmaceuticals EMANATE Phase 3 Misses Primary Endpoint, Sees Subgroup Signals for Setmelanotide
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Phase 3 top-line results from its EMANATE trial evaluating setmelanotide in four heterozygous genetic cohorts linked to MC4R pathway dysfunction, with company leadership describing the study as "statistically negative" on its prespecified primary endpoint but highlighting signals in select subgroups and lessons that could inform future development with next-generation assets. Trial
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)
PITTSBURGH, March 20, 2026 /PRNewswire/ -- PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it was selected by Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), as the exclusive U.S. Pharmacy distribution partner for the expanded indication of IMCIVREE® (setmelanotide) for adults and children 4 years of age and older living with acquired hypothalamic obesity.1 Acquired hypothalamic obesity is a rare disease characterized by accelerated and sustained weight gain caused by an injury to the hypothalamus. Acquired hypothalamic obesity most frequently follows the growth or treatment of craniopharyngioma, astrocytoma or other hypothalamic-pituitary tumors.
Price Targets
Rhythm Pharmaceuticals price target raised to $143 from $140 at Canaccord
$143.00
(was $96.61)
Canaccord Genuity
Rhythm Pharmaceuticals (RYTM) PT Raised to $143 at Wells Fargo
$143.00
(was $90.02)
Telsey Advisory
Rhythm Pharmaceuticals (RYTM) PT Raised to $143 at Wells Fargo
$143.00
(was $90.02)
Wells Fargo
Jefferies Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM): "We like RYTM into the next 6 months"
$125.00
(was $89.56)
Dennis Ding
·
Jefferies
Stifel Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
$131.00
(was $99.54)
Paul Matteis
·
Stifel Nicolaus
RBC Capital Starts Rhythm Pharmaceuticals (RYTM) at Outperform; 'Set' Up to Hit High Notes in Rare Obesity'
$145.00
(was $101.30)
Lisa Walter
·
RBC Capital
Rhythm Pharmaceuticals price target raised to $125 from $123 at H.C. Wainwright
$125.00
(was $101.63)
H.C. Wainwright
Rhythm Pharmaceuticals price target raised to $145 from $129 at Wells Fargo
$145.00
(was $101.63)
Derek Archila
·
Wells Fargo
Rhythm Pharmaceuticals price target raised to $123 from $110 at H.C. Wainwright
$123.00
(was $112.14)
Raghuram Selvaraju
·
H.C. Wainwright
Rhythm Pharmaceuticals price target raised to $140 from $120 at Guggenheim
$140.00
(was $112.45)
Seamus Fernandez
·
Guggenheim
Rhythm Pharmaceuticals price target raised to $157 from $141 at Goldman Sachs
$157.00
(was $117.52)
Goldman Sachs
Rhythm Pharmaceuticals price target raised to $141 from $114 at Canaccord
$141.00
(was $117.52)
Whitney Ijem
·
Canaccord Genuity
Rhythm Pharmaceuticals price target raised to $150 from $129 at Morgan Stanley
$150.00
(was $117.52)
Morgan Stanley
Rhythm Pharmaceuticals price target lowered to $139 from $157 at Goldman Sachs
$139.00
(was $111.18)
Corinne Johnson
·
Goldman Sachs
Rhythm Pharmaceuticals price target raised to $129 from $122 at Morgan Stanley
$129.00
(was $109.35)
Morgan Stanley
Rhythm Pharmaceuticals price target raised to $110 from $100 at H.C. Wainwright
$110.00
(was $99.16)
Raghuram Selvaraju
·
H.C. Wainwright
Rhythm Pharmaceuticals price target raised to $142 from $135 at Citizens JMP
$142.00
(was $98.76)
Jonathan Wolleben
·
JMP Securities
Rhythm Pharmaceuticals price target raised to $109 from $100 at Morgan Stanley
$109.00
(was $88.57)
Morgan Stanley
Rhythm Pharmaceuticals price target raised to $110 from $76 at Oppenheimer
$110.00
(was $89.04)
Leland Gershell
·
Oppenheimer
Rhythm Pharmaceuticals resumed with a Buy at Goldman Sachs
$97.00
(was $89.04)
Corinne Johnson
·
Goldman Sachs